Exeter Genomics Laboratory, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Medical Genetics Laboratory, Petrovsky National Research Centre of Surgery, Moscow, Russia.
Clin Genet. 2020 Oct;98(4):331-340. doi: 10.1111/cge.13812. Epub 2020 Aug 2.
Childhood dilated cardiomyopathy (DCM) is a leading cause of heart failure requiring cardiac transplantation and approximately 5% of cases result in sudden death. Knowledge of the underlying genetic cause can aid prognostication and clinical management and enables accurate recurrence risk counselling for the family. Here we used genomic sequencing to identify the causative genetic variant(s) in families with children affected by severe DCM. In an international collaborative effort facilitated by GeneMatcher, biallelic variants in PPP1R13L were identified in seven children with severe DCM from five unrelated families following exome or genome sequencing and inheritance-based variant filtering. PPP1R13L encodes inhibitor of apoptosis-stimulating protein of p53 protein (iASPP). In addition to roles in apoptosis, iASPP acts as a regulator of desmosomes and has been implicated in inflammatory pathways. DCM presented early (mean: 2 years 10 months; range: 3 months-9 years) and was progressive, resulting in death (n = 3) or transplant (n = 3), with one child currently awaiting transplant. Genomic sequencing technologies are valuable for the identification of novel and emerging candidate genes. Biallelic variants in PPP1R13L were previously reported in a single consanguineous family with paediatric DCM. The identification here of a further five families now provides sufficient evidence to support a robust gene-disease association between PPP1R13L and severe paediatric DCM. The PPP1R13L gene should be included in panel-based genetic testing for paediatric DCM.
儿童扩张型心肌病(DCM)是心力衰竭的主要原因,需要心脏移植,大约 5%的病例导致猝死。了解潜在的遗传原因可以帮助预测和临床管理,并为家庭提供准确的复发风险咨询。在这里,我们使用基因组测序来鉴定患有严重 DCM 的儿童的家族中的致病遗传变异。在 GeneMatcher 协助的国际合作努力下,在经过外显子或基因组测序以及基于遗传的变异过滤后,从五个无关家庭的七名患有严重 DCM 的儿童中发现了 PPP1R13L 的双等位基因变异。PPP1R13L 编码 p53 蛋白凋亡刺激蛋白抑制剂(iASPP)。除了在凋亡中的作用外,iASPP 还作为桥粒的调节剂,并与炎症途径有关。DCM 表现较早(平均:2 岁 10 个月;范围:3 个月-9 岁)且进展迅速,导致死亡(n = 3)或移植(n = 3),一名儿童目前正在等待移植。基因组测序技术对于鉴定新的和新兴候选基因非常有价值。PPP1R13L 的双等位基因变异以前在一个患有儿科 DCM 的单一近亲家庭中报道过。这里鉴定的另外五个家庭现在提供了足够的证据支持 PPP1R13L 与严重儿科 DCM 之间的稳健基因-疾病关联。PPP1R13L 基因应包含在儿科 DCM 的基于面板的基因测试中。